Cortexyme, Inc. Banner Image

Cortexyme, Inc. has reached its limit for free report views

Work for Cortexyme, Inc.? Upgrade Your Profile and unlock all your annual reports.

Cortexyme, Inc.

  • Ticker CRTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Cortexyme, Inc. Logo Image
  • 11-50 Employees
  • Based in South San Francisco, California
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing PhaseMore 2/3 clinical trial in patients with mild to moderate Alzheimer’s disease. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models.
Cortexyme, Inc.

Most Recent Annual Report

Cortexyme, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Cortexyme, Inc. has reached its limit for free report views.

Older/Archived Annual Reports